Nemolizumab Being Reviewed for AD, Prurigo Nodularis Nemolizumab Being Reviewed for AD, Prurigo Nodularis

For prurigo nodularis, the FDA has granted nemolizumab, a monoclonal antibody designed to inhibit interleukin-31 signaling, priority review.MDedge News

Source: Medscape Nurses Headlines - February 21, 2024 Category: Nursing Tags: Dermatology Source Type: news